Valvular & structural heart disease
Five‐year outcomes with self‐expanding versus balloon‐expandable transcatheter aortic valve implantation (TAVI) in patients with left ventricular systolic dysfunction
Main finding · All-cause mortalityResult — go to the resultAdjusted hazard ratio 1.44 95% CI 1.02–2.03Authors' conclusion
In the setting of LV systolic dysfunction, patients treated with a self-expanding THV had higher risk of 5-year mortality compared to patients treated with a balloon-expandable THV.
Study context
- Population
- Patients with severe aortic stenosis (AS) and LV ejection fraction (LVEF) <50% undergoing TAVI, Bern TAVI registry, August 2007–December 2022
- Participants
- 759 patients · 134 matched pairs
- Exposure
- Self-expanding vs balloon-expandable transcatheter heart valve (THV) for TAVI
- Outcome
- All-cause mortality
- Follow-up
- Up to 5 years
Methodological detailspropensity-score matched, registry-based (Bern TAVI registry)
- Propensity-score matched
- Registry-based (Bern TAVI registry)
Main finding
All-cause mortality
Adjusted hazard ratio
1.44
95% CI 1.02–2.03
P = 0.037
By group
Self-expanding vs Balloon-expandable
adjusted HR 1.44 (95% CI 1.02–2.03); P = 0.037
As reported in the abstract
Observational data: associations, not effects.
Further findings
Mean transvalvular gradient
P < 0.001
Technical success
- Achieved in over 85% of patients, similar in both groups
Other clinical outcomes · up to 5 years
- No significant differences between groups
Safety
≥mild-to-moderate paravalvular regurgitation
P < 0.001
Original publication
Five‐year outcomes with self‐expanding versus balloon‐expandable TAVI in patients with left ventricular systolic dysfunction. Am Heart J. Published 12 November 2024. doi:10.
Summarised from the published abstract; every number is checked against it